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survival(OS) at 3 years was 82% and at 5 years was 63%; IB2-
IIB 5yr: 70%; III 5yr: 27% (p: 0.01); For pN0 5yrs 74%; pN+ 
iliac-paraortic 5yr: 45% (p: 0.03).  
Dosimetric parameters: D90<6-7Gy(prescription dose) in 5p 
before 2011(since then interstitial implants were associated 
in 47%). The Local RFS: D90< 6Gy 87%, D90> 6Gy: 90% (p:ns); 
OS: D90< 6Gy 58%, D90> 6Gy: 67% (p:ns). D2cc-Sigma: 1.7-6.2 
Gy (md 3.8 Gy); D2cc-rectum: 2-6.1 (md 4.2); D2cc-bladder 
3.4-5.7 (md5.25). 
 
Conclusion: Use of intersticial HDR-BQ guided by RM 
increased CTV-HR dose and local control , like EMBRACE 
results. Nodal boost improves RDFS and perhaps OS. 
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Purpose or Objective: To elaborate the application of self-
made applicator which invented by our department (Patent 
No: 201420583680.X) in brachytherapy for recurrent cervical 
cancer at vaginal residue. This study especially pays 
attention to the doses evaluation of GTV and the OARs in 
brachytherapy by this technical.  
 
Material and Methods: 14 patients from 2013-2014 in our 
hospital who suffered from recurrent cervical cancer at 
vaginal residue in 0.5-3.5 years after radical hysterectomy 
and external beam radiotherapy (45 Gy/25 fractions) 
±chemotherapy ±brachytherapy were treated with MRI based 
and ultrasound guided brachytherapy using the self-made 
applicator. The self-made applicator was made of silica balls 
in matrix distribution connecting with a hole in front and 
behind it, making it formed into a straight line. The diameter 
of silica ball is 1 cm, the aperture of the hole is 1.5 mm. 
Therefore this self-made applicator could provide with the 
needle inserting smoothly and tidy and the depth of the 
needle can be adjusted. Moreover, this applicator can be 
used by superposition of multilayer, so it could be easily 
adapted to any shape. The prescribed dose of brachytherapy 
was 7 Gy×3-6 fractions, one week apart was planned. The 
GTV included the tumor, the CTV comprised the GTV with a 
10 mm circumferential margin and OARs were delineated. 
And then we recorded the GTV D90, D100 and D2cc of 
rectum, small intestines, bladder and sigmoid colon under 
the self-made applicator. 
 
Results: After plenty years of using the conventional 
applicators in brachytherapy, we found the radical 
hysterectomy cause the vaginal cuff end stenosis, the top of 
the conventional applicator, such as the Utrecht intertitial 
applicator cannot get close to the cancer region well which 
tumor invaded towards pelvic, so it was unable to achieve a 
high dose to the tumor, or it may induce an excess dose to 
normal tissues. In this research, we found the self-made 
applicator showed a high GTV dose and an acceptable OARs 
dose. Specifically, the GTV D90 and D100 for using self-made 
applicator were 724±64 cGy and 436±39 cGy, and the average 
D2cc for rectum, sigmoid colon and bladder was 370±21, 
265±16 and 423±44 cGy, the total dose when transformed to 
EQD2 models was under the constraints.  
 
Conclusion: The self-made applicator show excellent dose 
parameters on dose coverage and sparing exposure to OARs, 
which was more beneficial to the recurrent cervical cancer at 
vaginal residue invaded towards pelvic.  
 
EP-1975  
18F[FDG]PET guided brachytherapy for carcinoma of the 
uterine cervix 
S. Meregalli
1Ospedale S. Gerardo, Radiotheray, Monza, Italy 
1, G. Gardani1, S. Brenna1 
 
Purpose or Objective: Concomitant chemo-radiation and 
intracavitary brachytherapy (BT) is the standard treatment 
for locally advanced cervical carcinoma. In an our previous 
experience we reported the feasibility of [18F]FDG-PET in the 
BT treatment planning as functional imaging technique able 
to visualize neoplastic tissue. The purpose of this analysis 
was to evaluate, after an adequate follow-up, the site of 
recurrence and,in case of local relapse , if it was PET positive 
during BT. Survival and the late toxicity were also analysed. 
 
Material and Methods: From June 2007 to May 2010, thirteen 
women with locally advanced cervical carcinoma were 
enrolled into the study. All patients underwent external 
beam radiation therapy (EBRT) to whole pelvis (box 
technique to a total dose of 50.4 Gy) with weekly 
concomitant cisplatinum chemotherapy. HDR BT was 
performed weekly (5 Gy per fraction; 5 to 6 fractions). All BT 
fractions were planned by CT scan and, in the first and in the 
fourth fraction, FDG-PET/CT was also employed. Local 
control rate, progression free survival, overall survival and 
treatment related toxicities under RTOG criteria were 
evaluated 
 
Results: At the median follow-up of 61 months, the 
estimated 5-year progression-free survival (PFS) and the 5-
year overall survival (OS) were 56% and 70% respectively. The 
5-year local control rate was 84.6%. Only one patient had a 
local relapse corresponding to a PET positive area in BT 
guided planning. No G3-4 acute or late gastrointestinal or 
genitourinary toxicity has been recorded . 
 
Conclusion: In our experience, PET in BT planning of the 
cervical carcinoma gives some added useful information. The 
main goal of our analysis remains to define the site of 
possible recurrence: the recognition of a local relapse in PET 
positive area may suggest the opportunity of dose escalation 
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Purpose or Objective: To evaluate clinical outcomes and 
acute/late toxicities in patients with locally advanced 
cervical cancer treated with chemotherapy (CT) and external 
beam radiation therapy (EBRT), followed by high-dose rate 
brachytherapy (HDR-BRT) delivered with the Fletcher-
Williamson tandem and ovoid applicator 
 
Material and Methods: we evaluated 40 patients, median age 
57 years (range 40-83), treated between January 2007 and 
October 2014. According to FIGO classification, 10% were 
stage IB, 7,5% IIA, 45% IIB, 5% IIIA, 27,5% IIIB, 5% IV. All 
patients underwent pelvic +/- paraaortic EBRT (10/40 
patients); following the GEC-ESTRO recommendations, 
fractionation scheme for pelvic irradiation was 45-50.4 Gy in 
25-28 daily fractions (1.8 Gy/fr). The addition of a 
parametrial boost (10 Gy in 5 daily fractions) was performed 
in 10/40 patients (25 %). BRT with Fletcher applicator was 
performed in all patients after EBRT, with the fractionation 
scheme 22,5 Gy in 5 fractions (twice a day with 6 hours inter-
fraction interval). Concomitant CT was administrated in all 
patients, neoadjuvant CT was administrated in 15%. 
Treatment related toxicity was evaluated weekly during 
therapy and at each follow-up control, using RTOG/EORTC 
Radiation Morbidity Criteria. Response was investigated with 
periodical cervical cytology and CT scans; every treatment 
was evaluated in terms of BED10 and EQD2, with a median 
BED10 of 90.43 Gy (range 75.5-104.1) and median EQD2 of 
75.33 Gy (range 86.7-62.9). 
 
Results: With a median follow-up of 30 months (range 12-87), 
we observed acute/late genitourinary and gastrointestinal 
toxicity ≥ grade 2 in 10 % of patients, including one G4 GI 
acute toxicity (diarrhea requiring parenteral support) 
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occurred during concomitant EBRT-CT and resolved after a 
week of medical therapy. At 12 months from the end of 
treatment, response rate was 87.5% (35/40); we recorded 4 
persistent disease and 1 locoregional recurrence (after 6 
months), occurred in all patients with stage III. After 12 
months of follow-up,we reported disease progression (1 
central and 1 systemic) in 2 patients (5%), respectively at 17 
and 48 months from the end of radiation therapy. Patient 
showing central relapse underwent radical hysterectomy and 
patient with systemic disease started chemotherapy.  
 
Conclusion: In our experience, the association of 
concomitant EBRT-CT and HDR-BRT(Fletcher applicator) 
represents a well tolerated treatment for patients with 
advanced cervical cancer, with good results in terms of acute 
and late toxicity and local control 
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Purpose or Objective: To investigate the need for the 
implementation and development of immobilization and 
localization devices and other improvements in safety 
measures in addition to those currently in use in current HDR 
treatment protocols involving gynecological applicators.  
 
Material and Methods: 55 treatment plans from 27 cervical 
cancer patients treated with three to 5 intra-cavity cylinder 
insertions were used. We performed a retrospective study of 
a dosimetric evaluation due to a possible minor displacement 
of the cylinder after scanning to the treatment delivery time. 
The 55 plans that were dosimetrically analyzed post 
treatment involved treatments for 27 different patients. 22 
patients had a hysterectomy with bilateral salpingo-
oophorectomy . In 16 of these twenty two patients the 
procedure had an abdominal hysterectomy bilateral salpingo-
oophorectomy).Three of the patients had hysterectomies 
only. The vaginal cylinder applicators which were placed 
within the patients by a radiation oncologist for 
administering the treatments included the Capri, Miami, and 
multi-lumen catheres applicator. 
 
Results: For the 55 patients whose point dose data were 
gathered, dose variation at the hottest spot due to a 
simulated 1mm displacement in the superior inferior 
direction calculated by normalizing to the average of the 
endpoints was found to have a minimum value of 0.02% and a 
maximum value of 12.66% with an average value of 1.43% and 
a standard deviation of 2.02%. Dose variation at the hottest 
spot due to a simulated 1mm displacement in the medial 
lateral direction calculated by normalizing to the average of 
the endpoints was found to have a minimum value of 12.32% 
and a maximum value of 22.71% with an average value of 
16.96% and a standard deviation of 2.76%. The measurement 
of dose variation due to a displacement of one degree of 
rotation along the central axis of the applicator was found to 
have a minimum value of 0.00% and a maximum value of 
2.76% with an average value of 0.63% and a standard 
deviation of 0.62%.The standard deviation and the mean 
nearly coincide. The measurement of dose variation due to a 
displacement of five degrees of rotation along the central 
axis of the applicator was found to have a minimum value of 
0.06% and a maximum value of 13.71% with an average value 
of 2.15% and a standard deviation of 3.00%. 
 
Conclusion: The point dose variation due to hypothetical 1 
mm medial lateral displacement of a vaginal cylinder 
applicator make a difference in terms of Grade 1 rectal 
toxicity as defined by Common Terminology Criteria for 
Adverse Events v 4.0 in some patients receiving HDR VCBT 
alone or shortly after EBRT. The point dose variation due to 
hypothetical 1 mm medial lateral displacement of a vaginal 
cylinder applicator according to this analysis did reach a 
crudely obtained cutoff value for RTOG grade greater than or 
equal to 2 late rectal morbidity for any of the patients 
receiving HDR VCBT alone or shortly after EBRT. 
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Purpose or Objective: In some cervical cancer patients with 
extensive parametrial involvement, not all of the tumor can 
be sufficiently covered with MRI-based image guided 
brachytherapy using a standard intracavitary/interstitial 
applicator. An approach with individually designed applicator 
with oblique needles offers a possibility of better tumor dose 
coverage in these patients.In this study we tested the 
feasibility of the 3D printing for the individualized 
brachytherapy applicator add-on. 
 
Material and Methods: A patient in this case report study had 
extensive parametrial involvement to the pelvic wall. In 
order to improve the tumor dose coverage we decided to use 
additional oblique needles for the second application. A 
preplan for the second application was created based on the 
dosimetry information from the first application. The 
information on the optimal location of the oblique needles in 
the preplan was used to design an individualized interstitial 
template cap for the ring applicator, which was 
manufactured with a 3D printing technique. The whole 
procedure of the cap design and manufacture was performed 
in 5 days. 
 
Results: The HR-CTV coverage at the time of the first 
application (Figure 1a) was suboptimal (D90=69%, D100=35%, 
V100=77%).  
 
 
